Skip to main content
NCBI home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Mar;33(2):121–127. doi: 10.1007/BF01742540

Soluble interleukin-2 receptor and soluble CD8 antigen levels in serum from patients with non-resectable lung cancer

Jette Vibe-Petersen 1,✉, Niels Tvede 1, Marcus Diamant 1, Anne Arnt Kjerulff 1, Hans Rahbek Sørensen 3, Vagn Andersen 1
PMCID: PMC11038207  PMID: 1903673

Abstract

In a preliminary longitudinal study two women with histologically verified adenocarcinoma of the lung, without simultaneous infectious or inflammatory conditions, were seen every 2 weeks until death. In one of the patients serum soluble interleukin-2 receptor (sIL-2R) levels rose progressively while the levels for the other patient increased during the second half of the observation period. Serum soluble CD8 antigen (sCD8 Ag) showed a pattern dissimilar to the one for sIL-2R. In a retrospective cross-sectional study circulating levels of sIL-2R and sCD8 Ag were measured before explorative thoracotomy in a total of 65 patients with histologically proven non-resectable carcinoma of the lung. The sIL-2R levels were significantly increased independently of histological subclassification while sCD8 Ag was increased only in patients with small-cell lung cancer. There was no correlation between pre-operative values and length of survival.

Key words: Lung cancer, sIL-2R, Cytokines, CD8 antigen

References

  • 1.Brynskov J, Tvede N. Plasma interleukin-2 and a soluble/shed interleukin-2 receptor in serum of patients with Crohn's disease. The effect of cyclosporin. Gut. 1990;31:795. doi: 10.1136/gut.31.7.795. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Greene WC, Leonard WJ, Depper JM, Nelson DL, Waldman TA. The human interleukin-2 receptor: normal and abnormal expression in T cells and in leukemias induced the human T-lymphotropic retroviruses. Ann Intern Med. 1986;105:560. doi: 10.7326/0003-4819-105-4-560. [DOI] [PubMed] [Google Scholar]
  • 3.Hakim AA. Peripheral blood lymphocytes from patients with cancer lack interleukin-2 (IL-2) receptor expression: isolation of mRNA encoding IL-2R. Cancer Detect Prev. 1988;12:59. [PubMed] [Google Scholar]
  • 4.Holter W, Goldman CK, Casabo L, Nelson DL, Greene WC, Waldmann TA. Expression of functional IL-2 receptors by lipopolysaccharide and interferon-γ stimulated human monocytes. J Immunol. 1987;138:2917. [PubMed] [Google Scholar]
  • 5.Kloster BE, John PA, Miller LE, Rubin LA, Nelson DL, Blair DC, Tomar RH. Soluble interleukin-2 receptors are elevated in patients with AIDS or at risk of developing AIDS. Clin Immunol Immunopathol. 1987;45:440. doi: 10.1016/0090-1229(87)90095-x. [DOI] [PubMed] [Google Scholar]
  • 6.Miescher S, Whiteside TL, Carrel S, von Fliedner V. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumors: effects of tumor cells and their supernatants on proliferative responses of lymphocytes. J Immunol. 1986;136:1899. [PubMed] [Google Scholar]
  • 7.Nelson DL, Rubin LA, Kurman CC, Fritz ME, Boutin B. An analysis of the cellular requirements for the production of soluble interleukin-2 receptors in vitro. J Clin Immunol. 1986;6:114. doi: 10.1007/BF00918743. [DOI] [PubMed] [Google Scholar]
  • 8.Nou E. The natural five-year course in bronchial carcinoma. Cancer. 1984;53:2211. doi: 10.1002/1097-0142(19840515)53:10<2211::aid-cncr2820531035>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  • 9.Parkinson DR. Interleukin-2 in cancer therapy. Semin Oncol. 1988;15:10. [PubMed] [Google Scholar]
  • 10.Pitchenik AE, Guffee J, Stein-Streilein J. Lung natural killer and interleukin-2 activity in lung cancer. Am Rev Respir Dis. 1987;136:1327. doi: 10.1164/ajrccm/136.6.1327. [DOI] [PubMed] [Google Scholar]
  • 11.Pizzolo G, Chilosi M, Semenzato G. The soluble interleukin-2 receptor in haematological disorders. Br J Haematol. 1987;67:377. doi: 10.1111/j.1365-2141.1987.tb06156.x. [DOI] [PubMed] [Google Scholar]
  • 12.Pui C-H. Serum interleukin-2 receptor: clinical and biological implications (review) Leukemia. 1989;3:323. [PubMed] [Google Scholar]
  • 13.Pui C-H, Ip SH, Dodge RK, Carrabis S, Brown M, Crist WM, Berard CW, Kung P, Dahl GV, Murphy SB. Serum levels of CD8 antigen in childhood lymphoid malignancies: a possible indicator of increased suppressor cell activity in poor-risk patients. Blood. 1988;72:1015. [PubMed] [Google Scholar]
  • 14.Pui C-H, Ip SH, Thompson E, Dodge RK, Brown M, Wilimas J, Carrabis S, Kung P, Berard CW, Crist WM. Increased serum CD8 antigen level in childhood Hodgkin's disease relates to advanced stage and poor treatment outcome. Blood. 1989;73:209. [PubMed] [Google Scholar]
  • 15.Robb RJ, Greene WC, Rusk CM. Low and high affinity cellular receptors for interleukin-2: implications for the level of Tac antigen. J Exp Med. 1984;160:1126. doi: 10.1084/jem.160.4.1126. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Rubin LA, Kurman CC, Fritz ME, Biddison WE, Boutin B, Yarchoan R, Nelson DL. Soluble interleukin-2 receptors are released from activated human lymphoid cells in vitro. J Immunol. 1985;135:3172. [PubMed] [Google Scholar]
  • 17.Rubin LA, Kurman CC, Biddison WE, Goldman ND, Nelson DL. A monoclonal antibody 7G7/B6, binds to an epitope on the human interleukin-2 (IL-2) receptor that is distinct from that recognized by IL-2 or anti-Tac. Hybridoma. 1985;4:91. doi: 10.1089/hyb.1985.4.91. [DOI] [PubMed] [Google Scholar]
  • 18.Rubin LA, Jay G, Nelson DL. The released interleukin 2 receptor binds interleukin 2 efficiently. J Immunol. 1986;137:3841. [PubMed] [Google Scholar]
  • 19.Sacchi M, Heo DS, Dahl C, Johnson JT, Herberman RB, Whiteside TL. Interleukin 2 receptors on human squamous cell carcinoma lines. Proc Am Assoc Cancer Res. 1990;31:305. [Google Scholar]
  • 20.Semenzato G, Cipriani A, Trentin L, Zambello R, Masciarelli M, Vinante F, Chilosi M, Pizzolo G. High serum levels of soluble interleukin 2 receptors in sarcoidosis. Sarcoidosis. 1987;4:25. [PubMed] [Google Scholar]
  • 21.Smith KA. The interleukin in 2 receptor. Annu Rev Cell Biol. 1989;5:397. doi: 10.1146/annurev.cb.05.110189.002145. [DOI] [PubMed] [Google Scholar]
  • 22.Sørensen JB, Hansen HH (1989) Chemotherapy in adenocarcinoma of the lung cancer surveys 8: 671 [PubMed]
  • 23.Tomkinson BE, Brown MC, Ip SH, Carrabis S, Sullivan JL. Soluble CD8 during T cell activation. J Immunol. 1989;142:2230. [PubMed] [Google Scholar]
  • 24.Von Roenn J, Harris JE, Braun DP. Suppressor cell function in solid tumor cancer patients. Review article. J Clin Oncol. 1987;5:150. doi: 10.1200/JCO.1987.5.1.150. [DOI] [PubMed] [Google Scholar]
  • 25.Waldmann TA, Goldman CK, Robb RJ, Depper JM, Leonard WJ, Sharrow SO, Bongiovanni KF, Korsmeyer SJ, Greene WC. Expression of interleukin-2 receptors on activated human B cells. J Exp Med. 1984;160:1450. doi: 10.1084/jem.160.5.1450. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Wolf RE, Brelsford WG. Soluble interleukin-2 receptors in systemic lupus erythematosus. Arthritis Rheum. 1988;31:729. doi: 10.1002/art.1780310605. [DOI] [PubMed] [Google Scholar]
  • 27.Yang SC, Owen-Schaub L, Grimm EA, Roth JA. Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-α against primary lung cancer targets. Cancer Immunol Immunother. 1989;29:193. doi: 10.1007/BF00199995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Yasuda N, Takamatsu T, Kanoh T, Uchino H. Serum levels of soluble interleukin-2 receptor in patients with non-haematological disorders. Br J Haematol. 1988;69:573. doi: 10.1111/j.1365-2141.1988.tb02418.x. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES